Last reviewed · How we verify

DR REDDYS LABS SA — Portfolio Competitive Intelligence Brief

DR REDDYS LABS SA pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Trimethoprim TRIMETHOPRIM marketed Sulfonamide Antimicrobial [EPC] Dihydrofolate reductase Immunology 1973-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for DR REDDYS LABS SA:

Cite this brief

Drug Landscape (2026). DR REDDYS LABS SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dr-reddys-labs-sa. Accessed 2026-06-10.

Related